Precigen, Inc. (PGEN) fair value analysis
Nasdaq · Updated 2026-10-19
PGEN price how computed
Valuation status
Awaiting full valuationPGEN's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once PGEN's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $6.38
- Sector
- Healthcare
- 12-month range
- $3.10–$8.56
- Market cap
- $2.28B
- From 52-week high
- -25.4%
- Shares outstanding
- 357M
- Rank in Healthcare by quality score
- #159 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Precigen, Inc. is a biotechnology company that develops gene editing and cell therapy technologies for therapeutic applications. The company operates primarily in the United States within the healthcare and life sciences sector.
PGEN currently ranks #159 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.28B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $85.7M
- Net margin
- -184.0%
- EPS (TTM)
- $-1.10
- Gross margin
- 94.9%
- Debt / equity
- 2.26
- Revenue growth (3-yr avg)
- 1295.6%
- Shares outstanding
- 357M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $7.30
- 200-day average
- $5.17
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2017-01-19)
Earnings how computed
- Next earnings report
- 2026-11-12
- Last 8 quarters vs consensus
- 4 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+350.0%)
2026-03 ▲ beat (+50.0%)
2025-12 ▲ beat (+20.3%)
2025-09 ▼ miss (-1077.8%)
2025-06 ▬ met (0.0%)
2025-03 ▼ miss (-125.0%)
2024-12 ▲ beat (+33.3%)
2024-09 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 2 buy · 1 hold · 0 sell (3 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $13.7
- Target vs last price
- +114.6%
What our data shows for PGEN
- Shares are trading in the middle of their 12-month price range of $3.10–$8.56.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- PGEN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PGEN news
TickrTrends' derived news-sentiment signal for PGEN is currently leaning positive, computed from recent coverage.
- PGEN Initiates Coverage On B. Riley Securities -- Rating Set to Buy (gurufocus.com, 2026-09-25)
- PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Challenges (gurufocus.com, 2026-09-21)
- Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares (gurufocus.com, 2026-08-29)
TickrTrends take: Director Jeffrey Kindler's sale of 185,000 shares represents a significant insider transaction at Precigen, a Healthcare sector company currently awaiting full valuation assessment from TickrTrends. Large insider share dispositions can provide important signals about management's confidence in near-term prospects, making such transactions particularly relevant for investors evaluating the company's true valuation range. As TickrTrends works toward establishing comprehensive valuation metrics for PGEN, tracking patterns of insider buying and selling activity may help contextualize what company leadership believes about future value creation.
What people are saying
Follow the PGEN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for PGEN show a shift in trend state this week, with the 50/200-day trend moving from uptrend to mixed. The company operates in the Healthcare sector and currently has an awaiting full valuation verdict. This change in trend classification reflects a transition away from the sustained upward momentum that was present in the prior week.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PGEN stock undervalued?
PGEN's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is PGEN's TickrTrends verdict?
PGEN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once PGEN's own trailing P/E history validates under our standards.
How does PGEN compare to other Healthcare stocks?
PGEN ranks #159 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is PGEN overbought or oversold?
PGEN's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does PGEN pay a dividend?
PGEN has paid no dividend in the last twelve months; its last ex-dividend date on file was 2017-01-19.
When does PGEN report earnings next?
PGEN's next earnings report is scheduled for 2026-11-12, per the published earnings calendar.
Does PGEN usually beat earnings estimates?
Over its last 8 reported quarters PGEN beat the consensus estimate 4 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PGEN?
Of 3 analysts covering PGEN, 2 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $13.7 (+114.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.